Search

Your search keyword '"Sasaki, Koji"' showing total 2,577 results
Start Over Author "Sasaki, Koji"
2,577 results on '"Sasaki, Koji"'

402. Recurrent erysipelas led to diagnosis of hereditary hemorrhagic telangiectasia

Author

Yamaoka, Mari, Kanzawa, Yohei, Tatehara, Shun, Sasaki, Koji, Mizuki, Shimpei, Ohnishi, Jun, Nakajima, Takahiro, Ishimaru, Naoto, and Kinami, Saori

Subjects
Microbiology (medical), congenital, hereditary, and neonatal diseases and abnormalities, Infectious Diseases, hemic and lymphatic diseases, otorhinolaryngologic diseases, Case Report
Abstract

Hereditary hemorrhagic telangiectasia (HHT) is a risk of infection, such as by brain abscess associated with pulmonary arteriovenous malformations. However, association between HHT and recurrent erysipelas is not well described. HHT can cause vessel malformations in organs, leading to various serious outcomes. Prophylactic treatment is effective, but many people with HHT are undiagnosed. HHT is not described as a risk factor for soft tissue infection, but may increase the risk of serious infections requiring hospitalization. Our 72-year-old female patient was admitted for recurrent erysipelas. Pulmonary nodules indicated pulmonary arteriovenous fistula on chest computed tomography. By recognizing this combination, although seemingly unrelated problems, we could diagnose HHT and the patient could receive adequate treatment to prevent life-threatening events. The recurrent erysipelas was likely associated with HHT. Recurrent erysipelas is an important presentation which may facilitate early diagnosis of HHT.

Published
2022
Full Text
View/download PDF

403. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Author

Fiskus, Warren, Boettcher, Steffen, Daver, Naval, Mill, Christopher P., Sasaki, Koji, Birdwell, Christine E., Davis, John A., Takahashi, Koichi, Kadia, Tapan M., DiNardo, Courtney D., Jin, Qi, Qi, Yuan, Su, Xiaoping, McGeehan, Gerard M., Khoury, Joseph D., Ebert, Benjamin L., Bhalla, Kapil N., University of Zurich, and Bhalla, Kapil N

Subjects
2720 Hematology, Aminopyridines, Antineoplastic Agents, 610 Medicine & health, Article, Acute myeloid leukaemia, Targeted therapies, Cell Line, Tumor, Proto-Oncogene Proteins, hemic and lymphatic diseases, Humans, RC254-282, Gene Rearrangement, Sulfonamides, Gene Expression Regulation, Leukemic, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Histone-Lysine N-Methyltransferase, Hematology, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Oncology, Mutation, 10032 Clinic for Oncology and Hematology, Benzimidazoles, 2730 Oncology, Nucleophosmin, Myeloid-Lymphoid Leukemia Protein
Abstract

Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressing mutant (mt)-NPM1. Following MI treatment, although clinical responses are common, the majority of patients with AML with MLL1-r or mt-NPM1 succumb to their disease. Pre-clinical studies presented here demonstrate that genetic knockout or degradation of Menin or treatment with the MI SNDX-50469 reduces MLL1/MLL1-FP targets, associated with MI-induced differentiation and loss of viability. MI treatment also attenuates BCL2 and CDK6 levels. Co-treatment with SNDX-50469 and BCL2 inhibitor (venetoclax), or CDK6 inhibitor (abemaciclib) induces synergistic lethality in cell lines and patient-derived AML cells harboring MLL1-r or mtNPM1. Combined therapy with SNDX-5613 and venetoclax exerts superior in vivo efficacy in a cell line or PD AML cell xenografts harboring MLL1-r or mt-NPM1. Synergy with the MI-based combinations is preserved against MLL1-r AML cells expressing FLT3 mutation, also CRISPR-edited to introduce mtTP53. These findings highlight the promise of clinically testing these MI-based combinations against AML harboring MLL1-r or mtNPM1.

Published
2022
Full Text
View/download PDF

405. Early mortality after chemotherapy as a quality indicator—the leukemia perspective.

Author

Kantarjian, Hagop, Welch, Mary Alma, and Sasaki, Koji

Subjects
TERMINALLY ill, LEUKEMIA, DEATH rate, CANCER chemotherapy, MORTALITY
Abstract

The article discusses the use of early mortality rates as a measure of quality of care in cancer treatment, specifically in the context of leukemia. The article highlights the challenges and limitations of using early mortality rates as a quality indicator, including the diverse factors that can influence these rates such as tumor type, treatment intensity, and patient characteristics. The article argues that the use of early mortality rates as a quality measure should be more nuanced and take into account specific subsets of cancer and different lines of therapy. Additionally, the article emphasizes the importance of considering the potential benefits and risks of treatment in the last weeks of life for terminally ill cancer patients. Overall, the article suggests that a more comprehensive and individualized approach is needed when using early mortality rates as a quality indicator in leukemia care. [Extracted from the article]

Published
2023
Full Text
View/download PDF

406. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Author

Bazinet, Alexandre, Kadia, Tapan, Short, Nicholas J., Borthakur, Gautam, Wang, Sa A., Wang, Wei, Loghavi, Sanam, Jorgensen, Jeffrey, Patel, Keyur, DiNardo, Courtney, Daver, Naval, Alvarado, Yesid, Haddad, Fadi G., Pierce, Sherry, Nogueras Gonzalez, Graciela, Maiti, Abhishek, Sasaki, Koji, Yilmaz, Musa, Thompson, Philip, Wierda, William, Garcia-Manero, Guillermo, Andreeff, Michael, Jabbour, Elias, Konopleva, Marina, Huang, Xuelin, Kantarjian, Hagop, and Ravandi, Farhad

Abstract

•Using multivariate analysis, treatment intensity was not significantly associated with OS or CIR in patients with AML responding to therapy.•Achievement of MRD−CR should be considered a key objective in AML therapy.

Published
2023
Full Text
View/download PDF

407. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab

Author

Short, Nicholas J., primary, Macaron, Walid, additional, Konopleva, Marina, additional, Ravandi, Farhad, additional, Jain, Nitin, additional, Issa, Ghayas C., additional, Kadia, Tapan, additional, Sasaki, Koji, additional, Kebriaei, Partow, additional, Yilmaz, Musa, additional, Thompson, Philip A., additional, Takahashi, Koichi, additional, Abbas, Hussein A., additional, Wierda, William G., additional, Garris, Rebecca, additional, Kantarjian, Hagop M., additional, and Jabbour, Elias, additional

Published
2022
Full Text
View/download PDF

408. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib

Author

Sasaki, Yuya, primary, Kantarjian, Hagop M., additional, Short, Nicholas J., additional, Wang, Feng, additional, Furudate, Ken, additional, Uryu, Hidetaka, additional, Garris, Rebecca, additional, Jain, Nitin, additional, Sasaki, Koji, additional, Ravandi, Farhad, additional, Konopleva, Marina, additional, Garcia-Manero, Guillermo, additional, Little, Latasha, additional, Gumbs, Curtis, additional, Zhao, Li, additional, Futreal, P. Andrew, additional, Takahashi, Koichi, additional, and Jabbour, Elias, additional

Published
2022
Full Text
View/download PDF

410. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Author

Fiskus, Warren, primary, Boettcher, Steffen, additional, Daver, Naval, additional, Mill, Christopher P., additional, Sasaki, Koji, additional, Birdwell, Christine E., additional, Davis, John A., additional, Takahashi, Koichi, additional, Kadia, Tapan M., additional, DiNardo, Courtney D., additional, Jin, Qi, additional, Qi, Yuan, additional, Su, Xiaoping, additional, McGeehan, Gerard M., additional, Khoury, Joseph D., additional, Ebert, Benjamin L., additional, and Bhalla, Kapil N., additional

Published
2022
Full Text
View/download PDF

411. Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

Author

Reville, Patrick K., primary, Sasaki, Koji, additional, Kantarjian, Hagop M., additional, Daver, Naval G., additional, Yilmaz, Musa, additional, Dinardo, Courtney D., additional, Short, Nicholas J., additional, Borthakur, Gautam, additional, Pemmaraju, Naveen, additional, Mehta, Rohtesh S., additional, Pierce, Sherry, additional, Konoplev, Sergej N., additional, Khoury, Joseph D., additional, Garcia‐Manero, Guillermo, additional, Konopleva, Marina Y., additional, Jabbour, Elias, additional, Ravandi, Farhad, additional, and Kadia, Tapan M., additional

Published
2022
Full Text
View/download PDF

413. Results of Salvage Therapy with Mini-Hyper-CVD and Inotuzumab Ozogamicin with or Without Blinatumomab in Pre-B Acute Lymphoblastic Leukemia

Author

Kantarjian, Hagop, primary, Jain, Nitin, additional, Sasaki, Koji, additional, Jabbour, Elias, additional, Haddad, Fadi G., additional, Loghavi, Sanam, additional, Kanagal-Shamanna, Rashmi, additional, Jorgensen, Jeffrey, additional, Khouri, Issa, additional, Kebriaei, Partow, additional, Alvarado, Yesid, additional, Kadia, Tapan M., additional, Paul, Shilpa, additional, Garcia-Manero, Guillermo, additional, Dabaja, Bouthaina, additional, Yilmaz, Musa, additional, Jacob, Jovitta, additional, Garris, Rebecca, additional, O'Brien, Susan, additional, and Ravandi, Farhad, additional

Published
2022
Full Text
View/download PDF

416. NEW IDEA FOR DETERMINING THE OPTIMAL NUMBER OF MEASUREMENTS IN ABSORBED DOSE-TO-WATER MEASUREMENT OF HIGH-ENERGY PHOTON BEAM.

Author

Tsuno, Hayato, Sasaki, Koji, Matsubayashi, Fumiyasu, Koyama, Tomio, Oosaka, Akitane, Sakamoto, Masataka, Hosoki, Kazunori, Suzuki, Hidekazu, and Okano, Emiko

Subjects
PHOTON beams, ABSORBED dose, LINEAR accelerators, REFERENCE values
Abstract

This study presents a new idea for estimating the number of measurements required for determining the uncertainty in obtaining the desired water absorbed dose using the variation obtained from multicenter absorbed dose measurement data. The number of dose measurements depends on the performance of each linear accelerator (LINAC) tested and the dosimetry equipment and procedure used. However, optimising the number of data collected for the absorbed dose to water has been inadequately reported. Using the absorbed dose measurement data collected 10 times as a reference value, we will compare the changes in the variation of the measurement results caused by the difference in the number of repeated measurements of the absorbed dose. The number of measurements is determined statistically such that this variation would be smaller than the change in absorbed dose. Thus, we can determine the optimum number of measurements suitable for the variability of each LINAC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

417. A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.

Author

Bazinet, Alexandre, Darbaniyan, Faezeh, Kadia, Tapan M., Venugopal, Sangeetha, Kanagal‐Shamanna, Rashmi, DiNardo, Courtney D., Borthakur, Gautam, Jabbour, Elias J., Daver, Naval G., Pemmaraju, Naveen, Konopleva, Marina Y., Ravandi, Farhad, Sasaki, Koji, Chien, Kelly S., Hammond, Danielle, Pierce, Sherry A., Kantarjian, Hagop M., Garcia‐Manero, Guillermo, and Montalban‐Bravo, Guillermo

Subjects
ACUTE myeloid leukemia, CHRONIC leukemia
Abstract

Background: Patients with higher risk chronic myelomonocytic leukemia (CMML) have limited therapeutic options beyond hydroxyurea and hypomethylating agents (HMAs). Regimens based on a backbone of cladribine (CLAD), low‐dose cytarabine (LDAC), and an HMA are effective low‐intensity therapies for acute myeloid leukemia (AML). Methods: The authors conducted a retrospective chart review to evaluate the efficacy of CLAD/LDAC/HMA in CMML and secondary acute myeloid leukemia (sAML) arising from CMML. Responses were evaluated according to the 2006 International Working Group criteria for CMML and the 2017 European LeukemiaNet criteria for AML. The overall survival (OS), leukemia‐free survival (LFS), and duration of response were evaluated with the Kaplan–Meier method. Patients were stratified on the basis of prior HMA exposure. Results: The authors identified 21 patients with CMML (eight with HMA‐naive CMML and 13 with HMA‐failure CMML) and 33 patients with sAML (11 with HMA‐naive sAML and 22 with HMA‐failure sAML) treated with CLAD/LDAC/HMA‐based regimens. The CMML cohort was enriched for high‐risk features (proliferative type, elevated blasts, and RAS/MAPK mutations). The overall response rate was 33% in CMML (50% in HMA‐naive CMML and 23% in HMA‐failure CMML) and 48% in sAML (82% in HMA‐naive sAML and 32% in HMA‐failure sAML). The median OS was 14.4, 8.8, 42.9, and 2.9 months for HMA‐naive CMML, HMA‐failure CMML, HMA‐naive sAML, and HMA‐failure sAML, respectively. The median LFS was 14.4 and 3.9 months for HMA‐naive CMML and HMA‐failure CMML, respectively. Conclusions: CLAD/LDAC/HMA‐based regimens are effective in a subset of patients with higher risk CMML and sAML arising from CMML who have not previously experienced HMA failure. These findings must be confirmed in prospective studies. Cladribine and low‐dose cytarabine–based regimens are a therapeutic option for a subset of high‐risk patients with chronic myelomonocytic leukemia. These regimens are also effective after transformation to secondary acute myeloid leukemia in patients who have not previously experienced hypomethylating agent failure. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

418. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Author

Umezawa, Yoshihiro and Sasaki, Koji

Abstract

The therapeutic outcomes of chronic myeloid leukemia (CML) have improved dramatically since tyrosine kinase inhibitors (TKIs) became available in clinical practice. Life expectancy of patients with CML is now close to that of the general population. Patients with CML who achieve sustained deep molecular response may discontinue TKI therapy. However, most patients still require TKI therapy for long periods without sustained deep molecular response. Given the awareness of increased incidence of arterial occlusive events in patients on TKI therapy, the optimal TKI selection should be based on age, comorbidities, risk classification, and goals of treatment. Dose optimization of TKI therapy reduces the incidence of adverse events while maintaining efficacy in CML. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

419. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia.

Author

Paul, Shilpa, Kantarjian, Hagop, Sasaki, Koji, Marx, Kayleigh, Jain, Nitin, Savoy, J. Michael, DiPippo, Adam, Jammal, Nadya, Bravo, Guillermo Montalban, Kadia, Tapan, Garcia‐Manero, Guillermo, Short, Nicholas J., Ravandi, Farhad, and Jabbour, Elias

Published
2023
Full Text
View/download PDF

420. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.

Author

Cortes, Jorge E., Rea, Delphine, Mauro, Michael J., Tran, Diana, Wang, Pearl, Jadhav, Kejal, Yocolly, Aurore, and Sasaki, Koji

Subjects
CHRONIC myeloid leukemia, MEDICAL personnel, MEDICAL technology, HEALTH outcome assessment, MEDICAL care, MEDICAL economics
Abstract

To assess and compare health care resource utilization (HCRU) rates of asciminib and bosutinib at the Week 24, Week 48, and Week 96 cutoffs among 3 L + patients with chronic myeloid leukemia in chronic phase (CML-CP) in the randomized ASCEMBL trial. Patients in the ASCEMBL trial (Clinicaltrials.gov: NCT03106779) were randomized to receive asciminib 40 mg twice daily (n = 157) or bosutinib 500 mg once daily (n = 76). At each scheduled visit, investigators conducted HCRU assessment on hospitalization, emergency room visit, general practitioner visit, specialist visit and urgent care visit; duration and type of hospitalization for the hospitalized patients; and reasons for HCRU. The number of patients with HCRU, rate of HCRU per patient-year, and length of hospital stay by ward type were compared at Week 24, Week 48, and Week 96 analyses. Lower proportions of patients receiving asciminib versus bosutinib used any resources including hospitalizations, emergency room visits, general practitioner visits, specialist visits, and urgent care visits (23.6% versus 36.8%, 26.1% versus 39.5%, and 28.6% versus 42.6% at Week 24, Week 48, and Week 96 analyses, respectively). After normalizing for treatment exposure, rates of HCRU for any resource per patient-year were significantly lower for asciminib versus bosutinib: 0.25 (95% CI: 0.18–0.34) versus 0.80 (95% CI: 0.55–1.16) at the Week 24 analysis, 0.20 (95% CI: 0.15–0.27) versus 0.47 (95% CI: 0.32–0.66) at the Week 48 analysis, and 0.17 (95% CI: 0.12–0.22) versus 0.40 (95% CI: 0.27–0.55) at the Week 96 analysis. Among the hospitalized patients, mean length of hospital stay was lower for asciminib than bosutinib for most wards at all three timepoints. In the ASCEMBL trial, asciminib-treated patients with CML-CP in 3 L + maintained lower resource utilization compared to bosutinib over the long-term. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

422. Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour Ambulatory Blood Pressure: The JAMP Study

Author

Kario, Kazuomi, primary, Hoshide, Satoshi, additional, Narita, Keisuke, additional, Okawara, Yukie, additional, Kanegae, Hiroshi, additional, Aoki, Kenji, additional, Kihara, Hajime, additional, Koga, Toshiro, additional, Nakata, Tomoaki, additional, Oku, Kenji, additional, Matsuoka, Yasufumi, additional, Omori, Hiroaki, additional, Nishizawa, Masafumi, additional, Tanno, Yasuo, additional, Fukase, Yoko, additional, Omi, Koki, additional, Takahashi, Jun, additional, Mizuno, Hiroyuki, additional, Saito, Michiya, additional, Yatabe, Junichi, additional, Eguchi, Kazuo, additional, Iwashita, Kiyoshi, additional, Kumada, Maki, additional, Oki, Gaku, additional, Kabutoya, Tomoyuki, additional, Hojo, Yukihiro, additional, Ichida, Masaru, additional, Ishikawa, Shizukiyo, additional, Komori, Takahiro, additional, Matsui, Yoshio, additional, Matsumoto, Masatoshi, additional, Nagasaka, Shoichiro, additional, Nakano, Masahiro, additional, Nishimura, Yoshioki, additional, Okada, Kenta, additional, Shimada, Kazuyuki, additional, Shimpo, Masahisa, additional, Takahashi, Nozomu, additional, Uno, Hideyuki, additional, Ishikawa, Joji, additional, Kuroda, Toshio, additional, Hirahara, Nobutsune, additional, Kemi, Yuta, additional, Yoshioka, Hisashi, additional, Hoshi, Sakuo, additional, Mizuno, Atsuhi, additional, Ohno, Kunihiko, additional, Okazaki, Osamu, additional, Saito, Tsunehiro, additional, Tanaka, Tetsu, additional, Yamashiro, Kazuo, additional, Yamauchi, Tatsuyuki, additional, Yo, Shisei, additional, Yomogita, Shigeru, additional, Hikita, Sayaka, additional, Kawase, Yasuhiro, additional, Nojiri, Yoshifumi, additional, Sato, Yukihiro, additional, Uchiba, Kiyoshi, additional, Ishiguro, Motoyuki, additional, Taguchi, Atsushi, additional, Iida, Kazumasa, additional, Takemoto, Tatsuya, additional, Tone, Katsuyuki, additional, Abe, Hideyasu, additional, Abe, Yasuhisa, additional, Hasegawa, Masami, additional, Katsuya, Tomohiro, additional, Okada, Yoshiharu, additional, Tanaka, Shinichiro, additional, Tanke, Genyo, additional, Takami, Takeshi, additional, Michiura, Jun, additional, Shiotani, Masahiko, additional, Aoki, Tomohiro, additional, Ogura, Koichi, additional, Kawamura, Yuzuru, additional, Nakanishi, Shigekiyo, additional, Sasaki, Nobuo, additional, Takahashi, Toshiyuki, additional, Fujii, Akihisa, additional, Tanaka, Eiichiro, additional, Katayama, Hiroyuki, additional, Fukutomi, Motoki, additional, Miyoshi, Kosuke, additional, Naito, Hiroaki, additional, Yokota, Sawa, additional, Nakamura, Kazumasa, additional, Yokota, Tetsu, additional, Takasugi, Shinsuke, additional, Fujita, Shuichiro, additional, Fujita, Yumiko, additional, Kaneko, Hitoshi, additional, Fujiwara, Takeshi, additional, Kitamura, Wataru, additional, Anan, Yuhei, additional, Deguchi, Tomohiro, additional, Imaizumi, Yuki, additional, Miyagi, Jun, additional, Tsuji, Takahiro, additional, Uchiwa, Yasuhiro, additional, Ueda, Shin, additional, Yamaguchi, Takeya, additional, Yoshida, Tetsuro, additional, Yoshinaga, Ryo, additional, Maeda, Kosuke, additional, Kunitomo, Kotaro, additional, Soda, Kyousei, additional, Baba, Hirotoshi, additional, Yonezu, Keisuke, additional, Hino, Akihiro, additional, Miura, Genta, additional, Nakamura, Tomoko, additional, Kuroki, Munetoshi, additional, Omori, Fumihiko, additional, Hidaka, Toshiaki, additional, Hidaka, Takanori, additional, Yano, Yuichiro, additional, Kanemaru, Yoshimasa, additional, Kitani, Michitaka, additional, Koga, Masahiro, additional, Kubo, Hirohide, additional, Kuwabara, Masachika, additional, Miyata, Junichi, additional, Nagata, Masahiko, additional, Sasaki, Koji, additional, Tamaki, Noboru, additional, Tasaka, Hiroyasu, additional, Yokota, Naoto, additional, Miyata, Takahiro, additional, Katsuren, Eiyu, additional, Kudeken, Norifumi, additional, and Yagi, Noriharu, additional

Published
2021
Full Text
View/download PDF

424. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Author

Réa, Delphine, primary, Mauro, Michael J., additional, Boquimpani, Carla, additional, Minami, Yosuke, additional, Lomaia, Elza, additional, Voloshin, Sergey, additional, Turkina, Anna, additional, Kim, Dong-Wook, additional, Apperley, Jane F., additional, Abdo, Andre, additional, Fogliatto, Laura Maria, additional, Kim, Dennis Dong Hwan, additional, le Coutre, Philipp, additional, Saussele, Susanne, additional, Annunziata, Mario, additional, Hughes, Timothy P., additional, Chaudhri, Naeem, additional, Sasaki, Koji, additional, Chee, Lynette, additional, García-Gutiérrez, Valentin, additional, Cortes, Jorge E., additional, Aimone, Paola, additional, Allepuz, Alex, additional, Quenet, Sara, additional, Bédoucha, Véronique, additional, and Hochhaus, Andreas, additional

Published
2021
Full Text
View/download PDF

425. Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy

Author

Sasaki, Koji, primary, Kadia, Tapan, additional, Begna, Kebede, additional, DiNardo, Courtney D., additional, Borthakur, Gautam, additional, Short, Nicholas J., additional, Jain, Nitin, additional, Daver, Naval, additional, Jabbour, Elias, additional, Garcia‐Manero, Guillermo, additional, Bravo, Guillermo Montalban, additional, Masarova, Lucia, additional, Pierce, Sherry, additional, Konopleva, Marina, additional, Ravandi, Farhad, additional, Tefferi, Ayalew, additional, and Kantarjian, Hagop, additional

Published
2021
Full Text
View/download PDF

426. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Author

Daver, Naval, primary, Konopleva, Marina, additional, Maiti, Abhishek, additional, Kadia, Tapan M., additional, DiNardo, Courtney D., additional, Loghavi, Sanam, additional, Pemmaraju, Naveen, additional, Jabbour, Elias J., additional, Montalban-Bravo, Guillermo, additional, Tang, Guilin, additional, Sasaki, Koji, additional, Borthakur, Gautam, additional, Yilmaz, Musa, additional, Alvarez, Joie, additional, Golez, Michelle, additional, Pierce, Sherry A., additional, Nogueras González, Graciela M., additional, Ning, Jing, additional, Abbas, Hussein A, additional, Ravandi, Farhad, additional, Garcia-Manero, Guillermo, additional, and Kantarjian, Hagop, additional

Published
2021
Full Text
View/download PDF

428. A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

Author

Bazinet, Alexandre, primary, Kantarjian, Hagop, additional, Borthakur, Gautam, additional, Yilmaz, Musa, additional, Bose, Prithviraj, additional, Jabbour, Elias J., additional, Alvarado, Yesid, additional, Chien, Kelly S., additional, Pemmaraju, Naveen, additional, Takahashi, Koichi, additional, Short, Nicholas J., additional, Issa, Ghayas C., additional, Jain, Nitin, additional, Ferrajoli, Alessandra, additional, Burger, Jan A., additional, Bull Linderman, Debra, additional, Daver, Naval, additional, DiNardo, Courtney D., additional, Konopleva, Marina, additional, Garcia-Manero, Guillermo, additional, Sasaki, Koji, additional, Ravandi, Farhad, additional, and Kadia, Tapan M., additional

Published
2021
Full Text
View/download PDF

429. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia

Author

Lachowiez, Curtis, primary, DiNardo, Courtney D., additional, Takahashi, Koichi, additional, Loghavi, Sanam, additional, Xiao, Lian-Chun, additional, Kadia, Tapan M., additional, Daver, Naval, additional, Adeoti, Maria, additional, Short, Nicholas J., additional, Sasaki, Koji, additional, Wang, Sa A, additional, Borthakur, Gautam, additional, Issa, Ghayas C., additional, Maiti, Abhishek, additional, Alvarado, Yesid, additional, Pemmaraju, Naveen, additional, Montalban-Bravo, Guillermo, additional, Masarova, Lucia, additional, Yilmaz, Musa, additional, Jain, Nitin, additional, Andreeff, Michael, additional, Garcia-Manero, Guillermo, additional, Kornblau, Steven M., additional, Ravandi, Farhad, additional, Jabbour, Elias J., additional, Konopleva, Marina, additional, and Kantarjian, Hagop, additional

Published
2021
Full Text
View/download PDF

431. Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study

Author

Kim, Kunhwa, primary, Chien, Kelly S., additional, Ong, Faustine, additional, Kadia, Tapan M., additional, Jabbour, Elias J., additional, Alvarado, Yesid, additional, Sasaki, Koji, additional, Bueso-Ramos, Carlos E., additional, Kanagal-Shamanna, Rashmi, additional, Montalban-Bravo, Guillermo, additional, Dong, Xiao Qin, additional, Pierce, Sherry A., additional, Kantarjian, Hagop, additional, and Garcia-Manero, Guillermo, additional

Published
2021
Full Text
View/download PDF

432. Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Author

Darbaniyan, Faezeh, primary, Class, Caleb, additional, Montalban-Bravo, Guillermo, additional, Kanagal-Shamanna, Rashmi, additional, Estecio, Marcos, additional, Lu, Yue, additional, Soltysiak, Kelly A., additional, Chien, Kelly S., additional, Yang, Hui, additional, Sasaki, Koji, additional, Ganan-Gomez, Irene, additional, Colla, Simona, additional, Do, Kim-Anh, additional, Garcia-Manero, Guillermo, additional, and Wei, Yue, additional

Published
2021
Full Text
View/download PDF

433. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Author

Reville, Patrick K, primary, Kantarjian, Hagop, additional, Borthakur, Gautam, additional, Pemmaraju, Naveen, additional, DiNardo, Courtney D., additional, Sasaki, Koji, additional, Daver, Naval, additional, Issa, Ghayas C., additional, Ohanian, Maro, additional, Montalban-Bravo, Guillermo, additional, Short, Nicholas J., additional, Jain, Nitin, additional, Bhalla, Kapil N., additional, Jabbour, Elias J., additional, Ferrajoli, Alessandra, additional, Takahashi, Koichi, additional, Rausch, Caitlin R., additional, Malla, Rashmi, additional, Marek, Kelly, additional, Brandt, Mark, additional, Popat, Uday R., additional, Andreeff, Michael, additional, Garcia-Manero, Guillermo, additional, Konopleva, Marina, additional, Ravandi, Farhad, additional, and Kadia, Tapan M., additional

Published
2021
Full Text
View/download PDF

434. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors

Author

Haddad, Fadi, primary, Kantarjian, Hagop, additional, Jabbour, Elias J., additional, Issa, Ghayas C., additional, Garcia-Manero, Guillermo, additional, Ravandi, Farhad, additional, Konopleva, Marina, additional, Ferrajoli, Alessandra, additional, Kadia, Tapan M., additional, Pemmaraju, Naveen, additional, Takahashi, Koichi, additional, Alvarado, Yesid, additional, Yilmaz, Musa, additional, Borthakur, Gautam, additional, DiNardo, Courtney D., additional, Jain, Nitin, additional, Daver, Naval, additional, Short, Nicholas J., additional, Pierce, Sherry A., additional, Cortes, Jorge E., additional, and Sasaki, Koji, additional

Published
2021
Full Text
View/download PDF

435. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

Author

Short, Nicholas J., primary, DiNardo, Courtney D., additional, Daver, Naval, additional, Nguyen, Daniel, additional, Yilmaz, Musa, additional, Kadia, Tapan M., additional, Garcia-Manero, Guillermo, additional, Issa, Ghayas C., additional, Huang, Xuelin, additional, Qiao, Wei, additional, Sasaki, Koji, additional, Montalban-Bravo, Guillermo, additional, Chien, Kelly S., additional, Borthakur, Gautam, additional, Delumpa, Ricardo, additional, Milton, Anna, additional, Pierce, Sherry A., additional, Jabbour, Elias J., additional, Konopleva, Marina, additional, Kantarjian, Hagop, additional, and Ravandi, Farhad, additional

Published
2021
Full Text
View/download PDF

436. Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Author

Sasaki, Koji, primary, Jabbour, Elias J., additional, Issa, Ghayas C., additional, Naqvi, Kiran, additional, Skinner, Jeffrey, additional, Anderson, Kristin, additional, Dellasala, Sara E, additional, Yilmaz, Musa, additional, Ferrajoli, Alessandra, additional, Bose, Prithviraj, additional, Thompson, Philip A., additional, Alvarado, Yesid, additional, Jain, Nitin, additional, Garcia-Manero, Guillermo, additional, Takahashi, Koichi, additional, Burger, Jan A., additional, Borthakur, Gautam, additional, Pemmaraju, Naveen, additional, Haddad, Fadi, additional, Khouri, Maria R, additional, Paul, Shilpa, additional, Pierce, Sherry A., additional, Cortes, Jorge E., additional, and Kantarjian, Hagop, additional

Published
2021
Full Text
View/download PDF

437. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Author

Rivera, Daniel, primary, Kadia, Tapan M., additional, Montalban-Bravo, Guillermo, additional, Faderl, Stefan, additional, Sasaki, Koji, additional, Short, Nicholas J., additional, Daver, Naval, additional, DiNardo, Courtney D., additional, Masarova, Lucia, additional, Ferrajoli, Alessandra, additional, Jabbour, Elias J., additional, Borthakur, Gautham, additional, Al Azzawi, Hind, additional, Konopleva, Marina, additional, Garcia-Manero, Guillermo, additional, Andreeff, Michael, additional, Kantarjian, Hagop, additional, Ravandi, Farhad, additional, and Alvarado, Yesid, additional

Published
2021
Full Text
View/download PDF

438. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Author

Haddad, Fadi, primary, Kantarjian, Hagop, additional, Short, Nicholas J., additional, Sasaki, Koji, additional, Ravandi, Farhad, additional, Kebriaei, Partow, additional, Huang, Xuelin, additional, Jain, Nitin, additional, Konopleva, Marina, additional, Garcia-Manero, Guillermo, additional, Champlin, Richard E., additional, Kadia, Tapan M., additional, Takahashi, Koichi, additional, Daver, Naval, additional, Khoury, Joseph D., additional, Jorgensen, Jeffrey L., additional, Wang, Sa A, additional, Jacob, Jovitta, additional, Garris, Rebecca, additional, O'Brien, Susan M., additional, and Jabbour, Elias J., additional

Published
2021
Full Text
View/download PDF

439. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Author

Jain, Nitin, primary, Keating, Michael J., additional, Thompson, Philip A., additional, Ferrajoli, Alessandra, additional, Burger, Jan A., additional, Borthakur, Gautam, additional, Takahashi, Koichi, additional, Estrov, Zeev E., additional, Sasaki, Koji, additional, Kadia, Tapan M., additional, Konopleva, Marina, additional, Alvarado, Yesid, additional, Yilmaz, Musa, additional, DiNardo, Courtney D., additional, Bose, Prithviraj, additional, Ohanian, Maro, additional, Pemmaraju, Naveen, additional, Jabbour, Elias J., additional, Kanagal-Shamanna, Rashmi, additional, Patel, Keyur, additional, Wang, Wei, additional, Jorgensen, Jeffrey L., additional, Wang, Sa A, additional, Garg, Naveen, additional, Wang, Xuemei, additional, Wei, Chongjuan, additional, Cruz, Nichole, additional, Ayala, Ana, additional, Plunkett, William, additional, Kantarjian, Hagop, additional, Gandhi, Varsha, additional, and Wierda, William G., additional

Published
2021
Full Text
View/download PDF

440. Disease Characteristics of Multiple Myeloma Involving BRAF Mutations

Author

Mohamed, Shehab Fareed, primary, Khan, Maliha, additional, Quesada, Andres, additional, Ma, Junsheng, additional, Lin, Pei, additional, Yin, C. Cameron, additional, Sasaki, Koji, additional, Borthakur, Gautam, additional, Pemmaraju, Naveen, additional, Bashir, Qaiser, additional, Qazilbash, Muzaffar H., additional, Kaufman, Gregory P., additional, and Becnel, Melody R., additional

Published
2021
Full Text
View/download PDF

441. Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Author

Short, Nicholas J., primary, Kantarjian, Hagop, additional, Konopleva, Marina, additional, Desikan, Sai Prasad Prasad, additional, Jain, Nitin, additional, Ravandi, Farhad, additional, Huang, Xuelin, additional, Wierda, William G., additional, Borthakur, Gautam, additional, Sasaki, Koji, additional, Issa, Ghayas C., additional, Alvarado, Yesid, additional, Pemmaraju, Naveen, additional, Garcia-Manero, Guillermo, additional, DiNardo, Courtney D., additional, Thankachan, Jennifer, additional, Delumpa, Ricardo, additional, Milton, Anna, additional, Rivera, Juan, additional, Waller, Lourdes, additional, Garris, Rebecca, additional, and Jabbour, Elias J., additional

Published
2021
Full Text
View/download PDF

442. Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Author

Cherng, Hua-Jay J., primary, Khwaja, Raamis, additional, Kanagal-Shamanna, Rashmi, additional, Burger, Jan A., additional, Thompson, Philip A., additional, Ferrajoli, Alessandra, additional, Estrov, Zeev E., additional, Sasaki, Koji, additional, Sampath, Deepa, additional, Tang, Guilin, additional, Wang, Xuemei, additional, Kantarjian, Hagop, additional, Keating, Michael J., additional, Wierda, William G., additional, and Jain, Nitin, additional

Published
2021
Full Text
View/download PDF

443. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents

Author

Venugopal, Sangeetha, primary, Chien, Kelly S., additional, Hammond, Danielle, additional, Kanagal-Shamanna, Rashmi, additional, Sasaki, Koji, additional, Kadia, Tapan M., additional, DiNardo, Courtney D., additional, Konopleva, Marina, additional, Daver, Naval, additional, Ravandi, Farhad, additional, Pemmaraju, Naveen, additional, Short, Nicholas J., additional, Issa, Ghayas C., additional, Takahashi, Koichi, additional, Estrov, Zeev E., additional, Pierce, Sherry A., additional, Kantarjian, Hagop, additional, Garcia-Manero, Guillermo, additional, and Montalban-Bravo, Guillermo, additional

Published
2021
Full Text
View/download PDF

444. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial

Author

Maiti, Abhishek, primary, DiNardo, Courtney D., additional, Rausch, Caitlin R., additional, Pemmaraju, Naveen, additional, Garcia-Manero, Guillermo, additional, Ohanian, Maro, additional, Daver, Naval, additional, Issa, Ghayas C., additional, Borthakur, Gautam, additional, Ravandi, Farhad, additional, Alvarado, Yesid, additional, Kadia, Tapan M., additional, Short, Nicholas J., additional, Jabbour, Elias J., additional, Montalban-Bravo, Guillermo, additional, Jain, Nitin, additional, Kornblau, Steven M., additional, Masarova, Lucia, additional, Wierda, William G., additional, Sasaki, Koji, additional, Takahashi, Koichi, additional, Yilmaz, Musa, additional, Burger, Jan A., additional, Estrov, Zeev E., additional, Verstovsek, Srdan, additional, Andreeff, Michael, additional, Bose, Prithviraj, additional, Ferrajoli, Alessandra, additional, Thompson, Philip A., additional, Montalbano, Kathryn, additional, Vaughan, Kenneth, additional, Bivins, Carol A., additional, Pierce, Sherry A., additional, Qiao, Wei, additional, Ning, Jing, additional, Welch, John, additional, Kantarjian, Hagop, additional, and Konopleva, Marina, additional

Published
2021
Full Text
View/download PDF

446. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study

Author

Short, Nicholas J., primary, Montalban-Bravo, Guillermo, additional, Alvarado, Yesid, additional, Konopleva, Marina, additional, Jabbour, Elias J., additional, Garcia-Manero, Guillermo, additional, Yilmaz, Musa, additional, Jain, Nitin, additional, Borthakur, Gautam, additional, DiNardo, Courtney D., additional, Daver, Naval, additional, Issa, Ghayas C., additional, Ohanian, Maro, additional, Pemmaraju, Naveen, additional, Sasaki, Koji, additional, Maiti, Abhishek, additional, Chien, Kelly S., additional, Ravandi, Farhad, additional, Kadia, Tapan M., additional, Andreeff, Michael, additional, Muftuoglu, Muharrem, additional, Delumpa, Ricardo, additional, Bose, Prithviraj, additional, Pierce, Sherry A., additional, Waller, Lourdes, additional, Banks, Glenda, additional, Kantarjian, Hagop, additional, and Cortes, Jorge E., additional

Published
2021
Full Text
View/download PDF

447. Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Author

Mauro, Michael J., primary, Minami, Yosuke, additional, Rea, Delphine, additional, Hochhaus, Andreas, additional, Lomaia, Elza, additional, Voloshin, Sergey, additional, Turkina, Anna G., additional, Kim, Dong-Wook, additional, Apperley, Jane F, additional, Cortes, Jorge E., additional, Abdo, Andre N.R., additional, Fogliatto, Laura, additional, Kim, Dennis Dong Hwan, additional, le Coutre, Philipp D, additional, Saussele, Susanne, additional, Annunziata, Mario, additional, Hughes, Timothy P., additional, Chaudhri, Naeem A., additional, Chee, Lynette C.Y., additional, Garcia Gutierrez, Valentín, additional, Sasaki, Koji, additional, Kapoor, Shruti, additional, Allepuz, Alex, additional, Quenet, Sarah, additional, Bédoucha, Véronique, additional, and Boquimpani, Carla, additional

Published
2021
Full Text
View/download PDF

448. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

Author

Short, Nicholas J., primary, Kantarjian, Hagop, additional, Alvarado, Yesid, additional, Burger, Jan A., additional, Jain, Nitin, additional, Konopleva, Marina, additional, Ravandi, Farhad, additional, DiNardo, Courtney D., additional, Masarova, Lucia, additional, Sasaki, Koji, additional, Thompson, Philip A., additional, Ferrajoli, Alessandra, additional, Jacob, Jovitta, additional, Milton, Anna, additional, Garris, Rebecca, additional, and Jabbour, Elias J., additional

Published
2021
Full Text
View/download PDF

449. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy

Author

Pemmaraju, Naveen, primary, Wilson, Nathaniel R, additional, Garcia-Manero, Guillermo, additional, Sasaki, Koji, additional, Khoury, Joseph D., additional, Jain, Nitin, additional, Borthakur, Gautam, additional, Ravandi, Farhad, additional, Daver, Naval, additional, Kadia, Tapan M., additional, DiNardo, Courtney D., additional, Jabbour, Elias J., additional, Pierce, Sherry A., additional, Villarreal, John, additional, Qazilbash, Muzaffar H., additional, Konopleva, Marina, additional, and Kantarjian, Hagop, additional

Published
2021
Full Text
View/download PDF

450. Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

Author

Yilmaz, Musa, primary, Kantarjian, Hagop, additional, Short, Nicholas J., additional, Konopleva, Marina, additional, Kadia, Tapan M., additional, DiNardo, Courtney D., additional, Borthakur, Gautam, additional, Pemmaraju, Naveen, additional, Maiti, Abhishek, additional, Jabbour, Elias J., additional, Issa, Ghayas C., additional, Jain, Nitin, additional, Takahashi, Koichi, additional, Sasaki, Koji, additional, Ohanian, Maro, additional, Tang, Guilin, additional, Loghavi, Sanam, additional, Patel, Keyur, additional, Garcia-Manero, Guillermo, additional, Andreeff, Michael, additional, Ravandi, Farhad, additional, and Daver, Naval, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results